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Background: Quality of life (QoL) is an important outcome measure in the evaluation of
therapies for inflammatory bowel disease. The primary aim of this study was to determine the
effect of one year infliximab treatment on QoL and clinical parameters in pediatric patients with
Crohn's diseases (CD).
Methods: Our prospective study involved 51 children with conventional therapy resistant,
severe CD (mean age: 15.25 years, range: 11–18 years). Infliximab was given according to the
protocol (5 mg/kg, at weeks 0, 2, 6 and every 8 weeks). During the infliximab courses QoL of
patients was evaluated by IMPACT-III questionnaire at weeks 0, 6, 30 and 53. At the same time,
the Pediatric Crohn's Disease Activity Index (PCDAI) score was calculated. Moreover, serum
C-reactive protein (CRP), serum platelets and serum albumin were followed up. Auto-regressive,
cross-lagged models were used to assess relation between QoL and the clinical parameters.
Results: The initial IMPACT-III scores [median, percentile 25–75 (pc 25–75) at week 0: 115, 102.5–
130.25] increased significantly (p b 0.001) following infliximab therapy at week 54 (median: 141.5,IBD, inflammatory bowel disease; CD, Crohn's disease; UC, ulcerative colitis; PCDAI, Pediatric Crohn's
; CRP, C-reactive protein; ARCL, autoregressive cross-lagged model; χ2, Chi-square; df, degree of
LI, Tucker–Lewis Index; NNFI, non-normed fit index; RMSEA, Root Mean Square Error of Approximation;
R, maximum likelihood estimation robust
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Auto-regressive regression coefficients (β value) were significant between each variable over
time. The strongest cross-lagged relations were observed between IMPACT-III and serum albumin,
IMPACT-III and platelets. Reliability test of IMPACT-III revealed an excellent level of internal
consistency (Cronbach's alpha = 0.931).
Conclusion: Infliximab treatment has beneficial clinical effect which is confirmed by decrease
of PCDAI and increase of IMPACT-III. Autoregressive regression analysis showed regression
relation between IMPACT-III and PCDAI and laboratory parameters.
© 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.l, Autoregressive cross-laggedm
ns Colitis (2014), http://dx.doTable 1 Characteristics of the study population. 5-ASA:
5-aminosalicylic acid, IFX: infliximab.
Gender 21 male;
30 female
Mean age (year) [range] 15.25 [11–18]
Mean disease duration (year) [range] 2.29 [0.1–10]
Medical treatment when IFX therapy was
introduced (N)
Azathioprine + 5-ASA + steroid + antibiotic 4
Azathioprine + 5-ASA + steroid 11
Azathioprine + 5-ASA + antibiotic 4
Azathioprine + 5-ASA 24
5-ASA + antibiotic 3
5-ASA + steroid 1
Azathioprine 3
5-ASA 11. Introduction
Crohn's disease (CD), referred as a part of inflammatory bowel
disease (IBD), is a chronic inflammatory condition of the
gastrointestinal tract with strong impact on quality of life
(QoL). CD is induced by multi-factorial causes such as genetic,
environmental factors and pathological immune response.1
IBD can occur at any age, but most typically presents in
the second or third decade. However, recent international
studies reported permanent increase of IBD frequency in
childhood too. Based on Hungarian data, the incidence of
IBD in childhood (under 18 years) is 7.5/105 (CD: 4.7/105,
UC: 2.3/105), which corresponds with the internationally
published data.2–5
QoL is not well known in children and adolescent patients
with CD. Some studies have reported worse QoL in this
population than healthy ones.6,7 Moreover, cross-sectional
studies show an association of active CD with a poor QoL.8
The psychological health of children with CD may be closely
related to the somatic symptoms of CD. CD may issue in lack
of social integration and poor social functioning.9,10 To
examine this correspondence the IMPACT questionnaire was
specifically developed and validated to measure the disease
specific health relatedQoL of childrenwith IBD by Griffiths and
Otley et al.11 The questionnaire consists of 6 domains: bowel
symptoms, body image, functional/social impairment, emo-
tional impairment, tests/treatments and systemic impairment
which gives an overview of the patient's psychological status.12
As it has been noted in the original validation study, mean
IMPACT score varies significantly depending on the disease
severity. Otley et al. found that patients had significantly
better QoL half a year, then one year following the diagnosis
compared to the time at diagnosis.13
Over the last decade the introduction of anti-tumor
necrosis factor-alpha (TNF-α) drugs has dramatically changed
the treatment of IBD, especially in patients who are refractory
or intolerant to the conventional medication. One of these
biological agents is the infliximab (IFX) which is a new
therapeutic opportunity for patients with CD, including
pediatric population, refractory to conventional therapy. IFX
is a human–murine chimera monoclonal immunoglobulin G1
antibody which can block the soluble and membrane-attached
TNF-α, the most important pro-inflammatory cytokine in
IBD.14–16 Recent studies have reported the beneficial effect
of IFX in pediatric patients with CD. However, long term effect
and relation to QoL have not been well established.15,17–20
Therefore, the primary aim of our study was to analyze
the impact of IFX on QoL following one-year treatment. Our
secondary aim was to apply a new statistical methodology inod
i.orthis field to determine the interaction between QoL and
clinical parameters. Autoregressive cross-lagged association
permitted a complex analysis, wherein the QoL was in the
focus.2. Patients and methods
2.1. Patients
In our prospective study, performed at the 1st Department of
Pediatrics of Semmelweis University in Budapest, Hungary, 51
children with severe CD resistant for conventional therapy
(azathioprine, steroid) were involved. Of the 51 children 30
(58.8%) were girls, the mean age was 15.25 years (ranged:
11–18 years). The mean time since diagnosis was made
2.29 years (range: 0.1–10 years) (Table 1). The results of
IMPACT-III, the analysis of clinical indicators, like Pediatric
Crohn's Disease Activity Index (PCDAI)21 and laboratory
parameters were registered at every visits in 40 cases.3. Procedure and measures
IFX at a dose of 5 mg/kg intravenous infusion was applied as
induction therapy at weeks 0, 2 and 6, and as maintenance
therapy at every following 8 weeks, as it has been accepted by


















Figure 1 Standard presentation of the autoregressive cross-lagged model. : autoregressive association between parameters;
: cross-lagged association between parameters; A, B: measured parameters.
3Autoregressive cross-lagged models in children with Crohn’s diseasefor IFX treatment in pediatric CD.22 During infliximab therapy
course the QoL of the patients was assessed by IMPACT-III
questionnaire at weeks 0, 6, 30 as well as 53. At the same
time PCDAI score was also determined to assess the disease
severity. Moreover, some of the laboratory parameters like
serum C-reactive protein (CRP), serum platelet and serum
albumin were registered and followed.3.1. IMPACT-III
To measure health-related QoL for the first time in Hungary
(validated in 2008), the Canadian IMPACT-III questionnaire —
developed by Otley et al. has been applied at the 1st
Department of Pediatrics, Semmelweis University since
February, 2009. This specific self-report questionnaire was
developed for youth with IBD at the age between 8 and
17 years. It consists of 35 queries covering 6 domains: bowel
symptoms, systemic symptoms, emotional functioning, social
functioning, body image and treatment/interventions which
allow us to analyze each domain separately. Children indicated
the extent on a 5 point Likert scale towhich they are belonging
by specific aspects of their health condition. Possible scores
range from 35 to 175, the higher score indicates better QoL.11
In addition, PCDAI was registered and followed.214. Ethics
Written, informed consent was obtained from parents prior to
the procedure and the study was approved by the Semmelweis
University Regional and Institutional Committee and Research




Total IMPACT-III 115.0 (102.5, 130.25) 142.0
IMPACT-III bowel symptoms 3.571 (2.785, 4.25) 4.428
IMPACT-III systemic symptoms 2.833 (2.0, 3.333) 4.0
IMPACT-III emotional functioning 3.142 (2.285, 3.571) 4.0
IMPACT-III social functioning 3.583 (3.187, 3.972) 4.083
IMPACT-III body image 3.0 (2.416, 3.666) 3.50
IMPACT-III treatment/interventions 3.0 (2.333, 3.666) 3.666
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Based on results of Kolmogorov–Smirnov and Shapiro–Wilk
normality tests, datawere non-normal distribution. Therefore,
Friedman test and Wilcoxon single rank test with Bonferroni
analysis as post-hoc test were applied to follow up the changes
of each variable through the treatment period (IBM® SPSS®
20, Chicago, IL). p values lower than 0.05 were accepted as
statistically significant. In case of post-hoc analysis p values
lower than 0.008 were regarded as significant change.
Correlation between IMPACT-III and PCDAI was assessed by
Spearman's rank-order correlations (IBM® SPSS® 20, Chicago,
IL).
To test the reliability of IMPACT-III Cronbach's alpha was
determined (IBM® SPSS® 20, Chicago, IL).
To examine the relationships between QoL (IMPACT-III)
and clinical- and laboratory parameters an autoregressive
cross-lagged model (ARCL) was applied (Mplus 6.01). The
concept of the ARCL model is the following; the value at
the time of T is predicted by the value at the time of the
previous time, T − 1. The autoregressive pathways estimate
the association between IMPACT-III at four different times
(week 0, week 6, week 30, week 53). We can analyze the
association betweenweek 0 and week 6; week 6 and week 30,
as well as week 30 and week 53. Moreover, the cross-lagged
pathways allow us to measure the relation between IMPACT-III
and clinical factors (Fig. 1). Due to deviation from normal
distribution, in all structural equation modeling (SEM) analysis
maximum likelihood estimation robust to non-normality (MLR)
was used.23
To evaluate the overall model fit, absolute fit index
(chi-square value), comparative fit index (CFI), Tucker–Lewis
Fit Index or non-normed fit index (TLI or NNFI), and root meanr all 6 IMPACT-III domain separately. pc 25,75 = percentile 25
6 Week 30 Week 53
n (pc25,75) Median (pc25,75) Median (pc25,75)
(130, 148.75) 138.0 (126, 153) 141.50 (124.5, 153.75)
(4.035, 4.571) 4.428 (3.928, 4.571) 4.428 (3.892, 4.857)
(3.333, 4.583) 4.0 (3.333, 4.666) 4.0 (3.333, 4.333)
(3.178, 4.285) 3.785 (3.178, 4.285) 3.857(3.178, 4.428)
(3.75, 4.333) 4.208 (3.687, 4.562) 4.083 (3.75, 4.562)
(3.0, 3.666) 3.333 (3.0, 4.0) 3.666 (3.0, 4.0)
(2.666, 4.333) 3.666 (2.666, 4.333) 3.666 (3.0, 4.25)
els of IMPACT-III and Pediatric Crohn's Disease Activity indexes during
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Figure 2 Development of IMPACT-III scores with significance
at the definite times during one year IFX period. *** = p b 0.008.
Figure 3 Development of PCDAI scores with significance at the
definite times during one year IFX period. *** = p b 0.008, PCDAI =
Pediatric Crohn's Disease Activity Index.
4 D. Szabó et al.square error approximation (RMSEA) were calculated. CFI and
TLI reflect the total variance accounted for by the model and
indicate a fit relative to a null model. Values greater than 0.90
are desired, values greater than 0.95 indicate good fit, and
values greater than 0.90 indicate satisfactory fit. RMSEA
reflects the variance of residuals, values smaller than 0.08
indicate adequate fit while values smaller than 0.05 signify
excellent fit.24,25
6. Results
6.1. Results of Friedman test and Wilcoxon single
rank test with Bonferroni analysis
QoL of patients improved significantly due to IFX treatment
(χ2 = 58.101; p b 0.001). The IMPACT-III median scores at
week 0 (initial of infliximab treatment) and week 6 were 115
[pc 25,75: 102.5, 130.25] and 142 (pc 25,75: 130, 148.75),
respectively. After two infliximab infusion therapies the QoL
was significantly better than the initial score (Z = −5.846;
p b 0.001). Along the maintenance treatment the IMPACT-III
median was also higher atweek 30 andweek 53 than atweek 0,
138 (pc 25,75: 126, 153) and 141.5 (pc 25,75: 124.5, 153.75),
respectively, which indicated significant improvement in the
QoL during IFX therapy compared to initial status (Table 2,
Fig. 2).
The IMPACT-III questionnaire allows us to evaluate the 6
domains separately. Table 2 contains the calculated medianTable 3 Median scores of PCDAI and laboratory parameters. pc2
Crohn's Disease Activity Index, CRP = C-reactive protein.
Week 0 Week 6
Median (pc25,75) Median
PCDAI [–] 35 (25.0, 40.625) 10 (0,
Serum CRP [mg/L] 18.5 (3.750, 38.50) 1.5 (0,
Serum platelets [g/L] 516 (418, 684) 372 (31
Serum albumin [g/L] 41 (36, 43) 44 (40
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noticed better median score during the examined period
than at the time of initial. The systemic symptom domain
improved the most and the body image domain the least by
week 6 and week 53. Statistically, all domains improved
significantly during IFX course (p b 0.01).
The development of PCDAI was also assessed to monitor
the effect of the infliximab induction and maintenance
therapy. Results showed significant decrease in PCDAI (χ2 =
59.492, p b 0.001) during the period of one year infliximab
treatment compared to the initial scores. The median PCDAI
score was 35.0 (pc 25,75: 25, 40.625) atweek 0 and decreased
by 10.0 (pc 25,75: 0, 15.625) by week 6 (Z = −6.028;
p b 0.001). During maintenance therapy the PCDAI median
scoreswere 10.0 (pc 25,75: 5, 18.125) and 5.0 (pc 25,75: 0, 25)
at week 30 and week 53, respectively, which were significant
changes with respect to the initials (Table 3, Fig. 3).
Based on PCDAI scores, more than half of the patients were
in remission at every monitoring time: 58.8%, 65.1% and 61.9%
at week 6, week 30 and week 53, respectively. PCDAI b12.5
was regarded as a limit of remission.
Favorable changes in laboratory parameters were also
noticed. The serum CRP and platelets remarkably decreased,
and serum albumin significantly increased. The data are
depicted in Table 3 and Figs. 4–6 in detail.
Previous normality test showed that the data were not-
normal distribution, so Spearman's correlation tests were
run to assess the relationship between IMPACT III and PCDAI.5,75 = percentile 25 and percentile 75, PCDAI = Pediatric
Week 30 Week 53
(pc25,75) Median (pc25,75) Median (pc25,75)
15.625) 10 (5.0, 18.125) 5 (0, 25.0)
11.250) 3 (0, 12.250) 2.5 (0, 14.250)
0, 498) 368 (308, 475) 375 (310, 521)
, 46) 45 (41, 47) 44 (37, 47)
els of IMPACT-III and Pediatric Crohn's Disease Activity indexes during
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Figure 4 Development of CRP levels with significance at the
definite times during one year IFX period. *** = p b 0.008, CRP =
C-reactive protein.
Figure 6 Development of serumalbumin levels with significance
at the definite times during one year IFX period. *** = p b 0.008.
5Autoregressive cross-lagged models in children with Crohn’s diseasePreliminary analysis showed the relationship not to be
monotonic in every case, as assessed by visual inspection of
a scatter plot. There was a negative correlation between
IMPACT-III and PCDAI (Table 4.). The strongest relation was
observed at week 53 (Spearman's correlation coefficient =
−0.661).6.2. Analysis of reliability
Cronbach's alpha is 0.931, which indicates an excellent level
of internal consistency for our IMPACT-III scale with this
specific sample. Cronbach's alpha was also calculated if
particular item was deleted from the scale. Corrected item
total correlation was checked, 3 of the 35 questions were
lower than 0.25. However Cronbach's alpha did not change
considerably, the advance is not remarkable (Table 5).Figure 5 Development of platelet levels with significance at
the definite times during one year IFX period. *** = p b 0.008.
Please cite this article as: Szabó D, et al, Autoregressive cross-laggedmod
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To analyze the relation between QoL and other clinical
parameters four ARCL models were studied:Model 1: ARCL model of IMPACT-III and PCDAI
Model 2: ARCL model of IMPACT-III and CRP levels
Model 3: ARCL model of IMPACT-III and serum albumin
levels
Model 4: ARCL model of IMPACT-III and platelets levels.
Result of the nesting analysis showed that Model 1 was a
well-specified model, fitted the data the best: χ2 = 11.53,
CFI = 1.0, RMSEA = 0.0. CFI and RMSEA of the other 3 models
indicated poor fit (Table 6).
Excluding the regression of PCDAI between week 0 and
week 6 in Model 1, all autoregressive pathways between
the regular visits were significant within each model. These
findings were supported by autoregressive regression coeffi-
cients (β value) (Figs. 7–10). Moreover, the highest relation
was observed between week 30 andweek 53 in every grade. β
values and related critical ratios (CR) of the ARCL model of
IMPACT-III and PCDAI are summarized in detail in Table 7.
Cross-lagged association was observed between serum
level of CRP and IMPACT-III; serum level of albumin and
IMPACT-III; and level of platelet and IMPACT-III, however these
models did not fit well (Table 6, Figs. 8–10).Table 4 Results of correlation analysis between IMPACT-III
and PCDAI. ρ = Spearman's RankOrder Correlation Coefficient,
Sig. (2-tailed) = two-tailed significance level (p-value) of the
correlation coefficient.
Week 0 Week 6 Week 53
ρ −0.333 −0.39 −0.661
Sig. (2-tailed) 0.017 b0.005 b0.001
els of IMPACT-III and Pediatric Crohn's Disease Activity indexes during
/10.1016/j.crohns.2013.12.020











Question 30 110.700 521.194 0.109 0.624 0.933
Question 31 111.740 519.290 0.209 0.764 0.932
Question 33 111.460 515.876 0.245 0.644 0.931
6 D. Szabó et al.7. Discussion
This study has several important implications. Our results
support the reliability of IMPACT-III, the disease specific
health related QoL measure. Our findings also support the
effectiveness of IFX both on QoL and on PCDAI. To the best of
our knowledge this study is the first to report ARCL analysis
to evaluate the relation between QoL and IFX treatment
course. Though, we did not find a prospective relation
between QoL and PCDAI, one may argue that the direction of
the cross lagged regression coefficients between IMPACT-III
and PCDAI suggests that children who evaluate their QoL
being better will have lower values on PCDAI prospectively,
but having good PCDAI values do not guarantee high QoL
prospectively.
Previously, several studies reported successful usage of
ARCL model, particularly in psychological topic.26–28 In the
present study ARCL analysis was applied to measure the
prospective relationship between QoL and clinical parame-
ters. Out of the 4 examined models the model of IMPACT-III
and PCDAI (Model 1) fits well. However, the characterization
of other three models indicated poor fit. Thus, the results of
ARCL in these three cases have to be evaluated cautiously.
Necessarily, the QoL has been affected by several factors,
which effect lower model fit index. Presumably, more data
may reduce the effect of such external factors. In our trial
autoregression was seen in every model, except between
weeks 0 and 6 in the first model. The strongest relationship
between examined parameters developed between the time
at the last two data recording (weeks 30 and 53). This effect
may be explicated that after a half year treatment period
there were no remarkable changes in patient's condition
anymore.
Result of reliability test shows distinguished internal
consistency of IMPACT-III questionnaire. Otley et al. hadTable 6 Global fit of the autoregressive cross-laggedmodels.
χ2: Chi-square, df: degree of freedom, CFI: Comparative Fit
Index; TLI: Tucker–Lewis Index; RMSEA: Root Mean Square Error
of Approximation, PCDAI: Pediatric Crohn's Disease Activity
Index. Model 1: ARCL model of IMPACT-III and PCDAI; Model 2:
ARCL model of IMPACT-III and CRP levels; Model 3: ARCL model
of IMPACT-III and serum albumin levels;Model 4: ARCLmodel of
IMPACT-III and platelet levels.
χ2 df CFI TLI RMSEA
Model 1 11.525 12 1.000 1.005 0.000
Model 2 23.139 12 0.949 0.884 0.135
Model 3 24.283 12 0.940 0.865 0.143
Model 4 34.716 12 0.902 0.779 0.199
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questionnaire (α = 0.96).11 Kilroy and her colleagues had also
observed a high internal reliability (α = 0.90) of IMPACT-III,
similarly to a Croatian study (α = 0.92).7,29 The areas on which
participants indicated the most effect on QoL appeared to be
social functioning followed by bowel symptoms, emotional
functioning, treatment interventions, body image and sys-
temic symptoms. In contrast, results of our analysis repre-
sented the higher improvement in systemic symptoms
followed by bowel symptoms, emotional functioning, body
image, treatment interventions and social functioning. Only 3
questions had low inter-item correlation suggesting a need
for confirmatory factor analysis to test the proposed factor
structure of the instrument.
The results of this prospective study covering one year IFX
treatment period, suggest that treatment with IFX indicated
better QoL compared to initial status in children with severe
CD. Improvement of QoL during IFX treatment in CD has been
reported only in a few studies. One of the most important
clinical trials about the efficacy of IFX therapy in childhood
was the REACH study. In a part of this trial QoL was also
measured by IMPACT-III and the results indicated signifi-
cantly higher QoL during induction and maintenance IFX
treatment compared to the baseline values.22 De Boer and
his colleges examined the effect of IFX during on-going
therapy in children population. They assessed the changes in
quality of life with IMPACT-III and disease severity. During
on-going therapy a single dose of IFX resulted in decreased
CRP and improvement in QoL in patients who were
symptomatic at the time of treatment. After a single dose
of IFX initial IMPACT-III (day 0) score increased by day 14.30
A Spanish trial assessed the influence of the extended
biological treatments, like IFX and adalimumab, on IBD.
Results of this study demonstrated that most of the patients
with sustained response to adalimumab or IFX normalized
their perception of health. However, a group of patients,
mainly affected by CD, does not restore their health related
QoL to normal.31 A recent study from New Zealand suggested
moderate to strong negative correlation between the
PCDAI and Health Related QoL in pediatric patients with CD
(ρ = −0.596, p b 0.05), so did another research indicating
the higher disease activity the more diminished QoL in each
area.12,32
In line with QoL clinical indexes, PCDAI and laboratory
parameters were also significantly improved. As the results of
the REACH study showed, 56% of the patients who received IFX
maintenance treatment every 8 weeks were in remission at
week 54. In our study similar remission rate was observed, 62%
of the patients were in remission (defined as PCDAI ≤ 12.5)
after one year IFX therapy.22 The long-term outcome of IFX
therapy was also investigated in several studies.15,20,33,34 One

























Figure 7 Autoregressive cross-lagged association between IMPACT-III and PCDAI. ***: p b 0.001; **: p b 0.01; *: p b 0.05; +: p b 0.1;



























Figure 8 Autoregressive cross-lagged association between IMPACT-III and CRP. ***: p b 0.001; **: p b 0.01; *: p b 0.05; +: p b 0.1;
CRP: C-reactive protein.
7Autoregressive cross-lagged models in children with Crohn’s diseaseto IFX (55%) maintained benefits 3 years after IFX initiation
indicating a favorable result.18 Regarding the induction, the
mentioned studies had similar findings as our previous
research had; IFX initial therapy had good clinical efficacy in
most of the patients.35 Nevertheless, several previous trials
revealed the loss of this beneficial response. Primary and
secondary failures of IFX were observed in 10–30%, and 30–
40% of the patient, respectively.36,37 Our results showed lower
rate of primary and secondary loss of response at 6% and 20% of
the patients, respectively. However, the predictors of loss of
response were not examined in this study. Based on previous
observations concomitant immunosuppressive treatment
positively correlated with response to IFX.38 Episodic therapy
was associatedwith an increased likelihood for secondary non-
response. Interestingly, trials in the UK described that male
gender had a significantly lower chance for both primary and
secondary loss of response. The proposed explanation for that
finding reflects the fact that functional disorders, such as
irritable bowel syndrome, which may mimic the symptoms of
IBD, are more prevalent in the female population. However,
















Figure 9 Autoregressive cross-lagged association between IMPACT-I
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between IMPACT-III and PCDAI at week 53. However, the
association between these parameters at week 0 was very
low. Possible explanations for these findings may be that the
psychical status of these children was affected by several
factors. In case of relapse some patients may get used to
the alteration in their health status easier; moreover some
patient resigned their physical status.
In the present study efficacy of IFX was followed by
laboratory parameters. CRP has been used as a biomarker of
luminal inflammation and a predictor of the course of Crohn's
disease, as the present study also demonstrated it.40–46
Amount of platelets and serum albumin levels are known
as further standard markers of gut inflammation. According
to our findings, these markers improved significantly during
IFX course, which has confirmed the efficacy and anti-
inflammatory effect of IFX.
In conclusion, our study confirmed that one year IFX
treatment provided remission with sustained response in
more than half of the young patients with pediatric-onset














II and albumin. ***: p b 0.001; **: p b 0.01; *: p b 0.05; +: p b 0.1.




























Figure 10 Autoregressive cross-lagged association between IMPACT-III and platelets. ***: p b 0.001; **: p b 0.01; *: p b 0.05; +: p b 0.1.
Table 7 Parameter estimates of the base autoregressive cross-lagged Model 1.
Paths Standardized coefficients (β) Critical ratio
IMPACT (week 0)→ IMPACT (week 6) 0.714 8.622 ⁎⁎⁎
IMPACT (week 6)→ IMPACT (week 30) 0.728 6.312 ⁎⁎⁎
IMPACT (week 30)→ IMPACT (week 53) 0.928 12.904 ⁎⁎⁎
PCDAI (week 0)→ PCDAI (week 6) 0.107 0.752 (ns)
PCDAI (week 6)→ PCDAI (week 30) 0.356 1.899+
PCDAI (week 30)→ PCDAI (week 53) 0.582 3.455 ⁎⁎⁎
IMPACT (week 0)→ PCDAI (week 6) −0.203 −1.564 (ns)
IMPACT (week 6)→ PCDAI (week 30) −0.212 −1.236 (ns)
IMPACT (week 30)→ PCDAI (week 53) −0.265 −1.533 (ns)
PCDAI (week 0)→ IMPACT (week 6) 0.120 1.332 (ns)
PCDAI (week 6)→ IMPACT (week 30) −0.094 −0.580 (ns)
PCDAI (week 30)→ IMPACT (week 53) 0.000 −0.003 (ns)
⁎⁎⁎ p b 0.001; + p b 0.1; ns = non-significant; PCDAI: Pediatric Crohn's Disease Activity Index.
8 D. Szabó et al.in pediatric patients with CD. Moreover, they proved the
fact that QoL improves due to TNF-alpha antagonist therapy.
Autoregressive cross-lagged analysis showed autoregression
and cross-lagged association between QoL and clinical
parameters.Conflict of interest
The authors declare no conflict of interest.Acknowledgments
Gyöngyi Kökönyei and Gábor Veres acknowledge financial support of
the János Bolyai Research Fellowship awarded by the Hungarian
Academy of Sciences. This work was supported by OTKA-K 105530.
All authors have made substantial contribution to the
conception and design of the study and interpretation of
data. In addition, all authors have participated to create the
article and approved the submitted version.
Statement of authorship: DSz carried out the studies and
data analyses and drafted the manuscript. GyK participated
in the statistical analysis. AA participated in the design of the
study. AD participated the samples collection and analyses.
KM, KEM participated in the sample collection and writing of
the manuscript. PLL, MP participated in the design of the
study. BL, PG, ÁCs participated the samples collection and
statistical analysis. GV conceived of the study, and partici-
pated in design and coordination and helped to draft the
manuscript. All authors approved the submitted version.Please cite this article as: Szabó D, et al, Autoregressive cross-laggedmod
one year infliximab therapy..., J Crohns Colitis (2014), http://dx.doi.orReferences
1. Sanchez-Fayos Calabuig P, Martin Relloso MJ, Porres Cubero JC.
Multifactorial etiology and pathogenic factors in inflammatory
bowel disease. Gastroenterol Hepatol 2009;32:633–52.
2. Muller KE, Lakatos PL, Arato A, Kovacs JB, Varkonyi A, Szucs D,
et al. Incidence, Paris classification, and follow-up in a nationwide
incident cohort of pediatric patients with inflammatory bowel
disease. J Pediatr Gastroenterol Nutr 2013;57:576–82.
3. Kappelman MD, Rifas-Shiman SL, Kleinman K, Ollendorf D,
Bousvaros A, Grand RJ, et al. The prevalence and geographic
distribution of Crohn's disease and ulcerative colitis in the United
States. Clin Gastroenterol Hepatol 2007;5:1424–9.
4. Lehtinen P, Ashorn M, Iltanen S, Jauhola R, Jauhonen P, Kolho KL,
et al. Incidence trends of pediatric inflammatory bowel disease in
Finland, 1987–2003, a nationwide study. Inflamm Bowel Dis
2011;17:1778–83.
5. Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan
F, et al. Epidemiologic and clinical characteristics of childrenwith
newly diagnosed inflammatory bowel disease in Wisconsin: a
statewide population-based study. J Pediatr 2003;143:525–31.
6. Timmer A, Preiss JC, Motschall E, Rucker G, Jantschek G, Moser
G. Psychological interventions for treatment of inflammatory
bowel disease. Cochrane Database Syst Rev 2011:CD006913.
7. Kilroy S, Nolan E, Sarma KM. Quality of life and level of anxiety
in youths with inflammatory bowel disease in Ireland. J Pediatr
Gastroenterol Nutr 2011;53:275–9.
8. Akobeng AK, Suresh-Babu MV, Firth D, Miller V, Mir P, Thomas
AG. Quality of life in children with Crohn's disease: a pilot study.
J Pediatr Gastroenterol Nutr 1999;28:S37–9.
9. Rabbett H, Elbadri A, Thwaites R, Northover H, Dady I, Firth D,
et al. Quality of life in children with Crohn's disease. J Pediatr
Gastroenterol Nutr 1996;23:528–33.els of IMPACT-III and Pediatric Crohn's Disease Activity indexes during
g/10.1016/j.crohns.2013.12.020
9Autoregressive cross-lagged models in children with Crohn’s disease10. Engstrom I, Lindquist BL. Inflammatory bowel disease in children
and adolescents: a somatic and psychiatric investigation. Acta
Paediatr Scand 1991;80:640–7.
11. Otley A, Smith C, Nicholas D, Munk M, Avolio J, Sherman PM, et al.
The IMPACT questionnaire: a valid measure of health-related
quality of life in pediatric inflammatory bowel disease. J Pediatr
Gastroenterol Nutr 2002;35:557–63.
12. Hill R, Lewindon P, Muir R, Grange I, Connor F, Ee L, et al. Quality
of life in children with Crohn disease. J Pediatr Gastroenterol
Nutr 2010;51:35–40.
13. Otley AR, Griffiths AM, Hale S, Kugathasan S, Pfefferkorn M,
Mezoff A, et al. Health-related quality of life in the first year after
a diagnosis of pediatric inflammatory bowel disease. Inflamm
Bowel Dis 2006;12:684–91.
14. Ruemmele FM. Infliximab: how to use it in pediatric Crohn's
disease. J Pediatr Gastroenterol Nutr 2004;39:12–4.
15. de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor
treatment for pediatric inflammatory bowel disease. Inflamm
Bowel Dis 2012;18:985–1002.
16. Allez M. The multiple effects of tumour necrosis factor inhibitors
on immune cells: new insights on inhibition of activation and
cycling. Gut 2012;61:963–4.
17. Ruemmele FM, Lachaux A, Cezard JP, Morali A, Maurage C,
Ginies JL, et al. Efficacy of infliximab in pediatric Crohn's
disease: a randomized multicenter open-label trial comparing
scheduled to on demand maintenance therapy. Inflamm Bowel
Dis 2009;15:388–94.
18. Crombe V, Salleron J, Savoye G, Dupas JL, Vernier-Massouille G,
Lerebours E, et al. Long-term outcome of treatment with
infliximab in pediatric-onset Crohn's disease: a population-based
study. Inflamm Bowel Dis 2011;17:2144–52.
19. Veres G, Baldassano RN, Mamula P. Infliximab therapy for
pediatric Crohn's disease. Expert Opin Biol Ther 2007;7:1869–80.
20. Wanty C, Stephenne X, Sokal E, Smets F. Long-term outcome of
infliximab therapy in pediatric Crohn disease. Arch Pediatr
2011;18:863–9.
21. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM,
Kirschner BS, et al. Development and validation of a pediatric
Crohn's disease activity index. J Pediatr Gastroenterol Nutr
1991;12:439–47.
22. Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns
J, et al. Induction and maintenance infliximab therapy for the
treatment of moderate-to-severe Crohn's disease in children.
Gastroenterology 2007;132:863–73 (quiz 1165–6).
23. Muthén LK, Muthén BO. Mplus user's guide. Sixth ed. Los
Angeles: Muthén & Muthén; 1998–2010.
24. Browne MWC R. Alternative ways of assessing model fit. In:
Bollen KA, Long JS, editors. Testing structural equation models.
Beverly Hills; 1993.
25. Bentler PM. Comparative fit indexes in structural models.
Psychol Bull 1990;107:238–46.
26. Arnett AB, Pennington BF, Willcutt E, Dmitrieva J, Byrne B,
Samuelsson S, et al. A cross-lagged model of the development of
ADHD inattention symptoms and rapid naming speed. J Abnorm
Child Psychol 2012;40:1313–26.
27. Hanson LL, Akerstedt T, Naswall K, Leineweber C, Theorell T,
Westerlund H. Cross-lagged relationships between workplace
demands, control, support, and sleep problems. Sleep 2011;34:
1403–10.
28. Song TM, An JY, Hayman LL, KimGS, Lee JY, Jang HL. A three-year
autoregressive cross-lagged panel analysis on nicotine depen-
dence and average smoking. Healthc Inf Res 2012;18:115–24.
29. Abdovic S, Mocic Pavic A, Milosevic M, Persic M, Senecic-Cala I,
Kolacek S. The IMPACT-III (HR) questionnaire: a valid measure ofPlease cite this article as: Szabó D, et al, Autoregressive cross-laggedmod
one year infliximab therapy..., J Crohns Colitis (2014), http://dx.doi.orghealth-related quality of life in Croatian children with inflam-
matory bowel disease. J Crohns Colitis 2013;7:908–15.
30. DeBoer MD, Barnes BH, Stygles NA, Sutphen JL, Borowitz SM.
Changes in inflammation and QoL after a single dose of infliximab
during ongoing IBD treatment. J Pediatr Gastroenterol Nutr
2012;54:486–90.
31. Casellas F, Robles V, Borruel N, Torrejon A, Castells I, Navarro E,
et al. Restoration of quality of life of patients with inflammatory
bowel disease after one year with antiTNFalpha treatment. J
Crohns Colitis 2012;6:881–6.
32. Lowe W, Kenwright D, Wyeth J, Blair N. Crohn disease: effect on
children's lifestyles. J Pediatr Gastroenterol Nutr 2012;54:
397–400.
33. Hyams J, Walters TD, Crandall W, Kugathasan S, Griffiths A,
Blank M, et al. Safety and efficacy of maintenance infliximab
therapy for moderate-to-severe Crohn's disease in children:
REACH open-label extension. Curr Med Res Opin 2011;27:651–62.
34. De Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM,
Kneepkens CM, et al. The duration of effect of infliximab
maintenance treatment in paediatric Crohn's disease is limited.
Aliment Pharmacol Ther 2011;33:243–50.
35. Veres G, Szabo D, Varkonyi A, Tari B, Polgar M, BK J, et al. Analysis
of infliximab treated pediatric patients with Crohn disease in
Hungary. Orv Hetil 2010;151:179–83.
36. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M,
Chowers Y, et al. The London Position Statement of the World
Congress of Gastroenterology on Biological Therapy for IBD with
the European Crohn's and Colitis Organization: when to start,
when to stop, which drug to choose, and how to predict response?
Am J Gastroenterol 2011;106:199–212 (quiz 213).
37. Yanai H, Hanauer SB. Assessing response and loss of response to
biological therapies in IBD. Am J Gastroenterol 2011;106:685–98.
38. Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M,
Belaiche J, et al. Demographic and clinical parameters influencing
the short-term outcome of anti-tumor necrosis factor (infliximab)
treatment in Crohn's disease. Am J Gastroenterol 2002;97:
2357–63.
39. Sprakes MB, Ford AC, Warren L, Greer D, Hamlin J. Efficacy,
tolerability, and predictors of response to infliximab therapy for
Crohn's disease: a large single centre experience. J Crohns
Colitis 2012;6:143–53.
40. Desai D, Faubion WA, Sandborn WJ. Review article: biological
activitymarkers in inflammatory bowel disease.Aliment Pharmacol
Ther 2007;25:247–55.
41. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as
a marker for inflammatory bowel disease. Inflamm Bowel Dis
2004;10:661–5.
42. Liu S, Ren J, Han G, Wang G, Gu G, Xia Q, et al. Mean platelet
volume: a controversial marker of disease activity in Crohn's
disease. Eur J Med Res 2012;17:27.
43. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel
disease: current practices and recent advances. Transl Res
2012;159:313–25.
44. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS.
Infliximab improves inflammation and anthropometric measures
in pediatric Crohn's disease. J Gastroenterol Hepatol 2010;25:
810–6.
45. Assa A, Hartman C, Weiss B, Broide E, Rosenbach Y, Zevit N, et al.
Long-term outcome of tumor necrosis factor alpha antagonist's
treatment in pediatric Crohn's disease. J Crohns Colitis 2013;7:
369–76.
46. De Greef E, Mahachie John JM, Hoffman I, Smets F, Van Biervliet
S, Scaillon M, et al. Profile of pediatric Crohn's disease in Belgium.
J Crohns Colitis 2013;7:e588–98.els of IMPACT-III and Pediatric Crohn's Disease Activity indexes during
/10.1016/j.crohns.2013.12.020
